Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether terlipressin is safe and effective in the
treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.